B+
Bull case
20%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
FBIO
Fortress BiotechANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+88.8
Score
AI commentary
Official Q2 filing tone is constructive on revenue growth, Emrosi payer access, launched-product royalties, and partnered-program progress [#SEC-8K-2026-08-13]. However, quantified social, options, short-interest, employee-sentiment, analyst-revision, and post-print price-reaction data are unavailable; missing data are not positive evidence. This remains a cautious monitoring-to-speculative-upside view.
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-08eventRoyalty realization from launched productsHigh impact
Fortress reported royalties generated from launches of ZYCUBO and UNLOXCYT, creating potential recurring royalty income. Magnitude and timing of future royalties are not disclosed [#SEC-8K-2026-08-13].
2026-12-08eventAnselamimab regulatory pathwayHigh impact
AstraZeneca reported prespecified anselamimab subgroup results and indicated plans to submit the findings to regulatory authorities. Submission timing and regulatory outcomes remain undisclosed [#SEC-8K-2026-08-13].
2026-12-08catalystEmrosi payer-access expansionHigh impact
Fortress reported that subsidiary Journey Medical expanded Emrosi payer access to more than 150 million commercial lives. Further commercialization could support product-revenue growth, but conversion from access to prescriptions remains uncertain [#SEC-8K-2026-08-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology